Cough and cold:

Indications for: ZUTRIPRO ORAL SOLUTION

Cough and nasal congestion associated with upper-respiratory allergies or common cold.

Adult Dosage:

Use accurate measuring device. ≥18yrs: 5mL every 4–6hrs as needed. Max: 4 doses (20mL) per 24hrs.

Children Dosage:

<18yrs: not established.

ZUTRIPRO ORAL SOLUTION Contraindications:

During or within 14 days of MAOIs. Narrow angle glaucoma. Urinary retention. Severe hypertension. Severe coronary artery disease.

Boxed Warning:

Risks from concomitant use with benzodiazepines or other CNS depressants.

ZUTRIPRO ORAL SOLUTION Warnings/Precautions:

Risks from concomitant benzodiazepines or other CNS depressants (see Interactions). Discontinue if respiratory depression occurs. Abuse potential (monitor). Avoid in head injury, other intracranial lesions or pre-existing increase in intracranial pressure. Acute abdomen. Cardiovascular disorders. Diabetes. Thyroid disorders. Addison's disease. Prostatic hypertrophy. Urethral stricture. Asthma. Severe hepatic or renal impairment. Elderly. Labor & delivery. Pregnancy (Cat.C). Nursing mothers: not recommended.

ZUTRIPRO ORAL SOLUTION Classification:

Antitussive + antihistamine + sympathomimetic.

ZUTRIPRO ORAL SOLUTION Interactions:

See Contraindications. Increased risk of respiratory depression, sedation with benzodiazepines or other CNS depressants (eg, opioids, antihistamines, antipsychotics, anxiolytics, alcohol); avoid. Hypertensive crisis with MAOIs. May affect or be affected by TCAs. Paralytic ileus may occur with anticholinergics

Adverse Reactions:

Sedation, somnolence, mental clouding, lethargy, impairment of mental and physical performance, anxiety, fear, dysphoria, dizziness, psychic dependence, mood changes, nervousness or sleeplessness, visual disturbances, confusion, headache, euphoria, facial dyskinesia, feeling faint, lightheadedness, agitation, restlessness, insomnia, irritability, tremor; respiratory depression, cardiovascular effects.

How Supplied:

Soln—480mL